According to filings with the U.S. Securities and Exchange Commission, MaraBio Systems is raising up to $28,958,242.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Michael Paul played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MaraBio Systems
We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.

To learn more about MaraBio Systems, visit http://marabio.com/
MaraBio Systems Linkedin Page: https://www.linkedin.com/company/marabio-inc/

Contact:
Michael Paul, President and Chief Executive Officer
801-580-4514
https://www.linkedin.com/in/michael-s-paul/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.